AN2 Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
ANTX$4.000.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
AN2 THER APEUTICS, INC.
CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-In · Accumulated Other Comprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Gain (Loss) | Deficit | Equity | |
| Balances at December 31, 2024 | 29,919,634 | $— | $287,594 | $31 | $(205,776) | $81,849 |
| Issuance of common stock under the ESPP | 42,797 | — | 38 | — | — | 38 |
| Issuance of common stock upon exercise of stock options | 63,124 | — | 27 | — | — | 27 |
| Issuance of common stock upon release of restricted stock units | 115,962 | — | — | — | — | — |
| Stock-based compensation | — | — | 2,047 | — | — | 2,047 |
| Unrealized gain on available-for-sale investments | — | — | — | 17 | — | 17 |
| Net loss | — | — | — | — | (10,649) | (10,649) |
| Balances at March 31, 2025 | 30,141,517 | $— | $289,706 | $48 | $(216,425) | $73,329 |
| Common Stock · AdditionalPaid-In · Accumulated Other Comprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Gain (Loss) | Deficit | Equity | |
| Balances at December 31, 2023 | 29,741,445 | $— | $278,881 | $275 | $(154,455) | $124,701 |
| Issuance of common stock under the ESPP | 45,288 | — | 124 | — | — | 124 |
| Issuance of common stock upon exercise of stock options | 28,930 | — | 225 | — | — | 225 |
| Vesting of early exercised stock options | — | — | 1 | — | — | 1 |
| Stock-based compensation | — | — | 2,385 | — | — | 2,385 |
| Unrealized loss on available-for-sale investments | — | — | — | (222) | — | (222) |
| Net loss | — | — | — | — | (16,617) | (16,617) |
| Balances at March 31, 2024 | 29,815,663 | $— | $281,616 | $53 | $(171,072) | $110,597 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.